Haemophilus Influenzae Type b Conjugate Vaccine (Yuxi Walvax Biotechnology)

b型流感嗜血杆菌结合疫苗（玉溪沃森生物）

Report date: 2022/01/14 13:23:58

Base Information

Drug NameHaemophilus Influenzae Type b Conjugate Vaccine (Yuxi Walvax Biotechnology)
Drug Alias NameN/A
ClassificationVaccines > Application > Prophylactic vaccineVaccines > National Immunization Program > Non-immunization program vaccine(Class II)Vaccines > Development/production technology > Conjugated vaccine +[4] 
Mechanisms of ActionImmunostimulants
TargetsNot applicable
Therapy Area/IndicationsHaemophilus Infections
Global Approved IndicationsHaemophilus Infections
Approved Indications in ChinaHaemophilus Infections
Original Approved Country/TerritoryMainland China
Original Approved Date2007/04/02
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesYuxi Walvax Biotechnology Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesYuxi Walvax Biotechnology Co Ltd
Inactive CompaniesN/A
Active IndicationsHaemophilus Infections
Inactive IndicationsN/A

Other Information

ATC CodeJ07AG01
Related LinksN/A